Ergot derivative; dihydrogenated analog of lisuride, q.v. Exhibits dopamine agonist and antagonist activity. Prepn: V. Zikán et al., Collect. Czech. Chem. Commun. 37, 2600 (1972); eidem, DE 2238540; eidem, US 3953454 (1973, 1976 both to Spofa). Physical properties: A. Cerny et al., Collect. Czech. Chem. Commun. 52, 1331 (1987). Pharmacology in animals and humans: H. Wachtel, R. Dorow, Life Sci. 32, 421 (1983). Receptor binding studies in rat brain: W. Kehr et al., Acta Pharm. Suec. 1983, Suppl. 2, 98; M. W. Valchár et al., Eur. J. Pharmacol. 136, 97 (1987). Evaluation in animal models of Parkinson's disease: W. C. Koller, G. Herbster, Neurology 37, 723 (1987); T. Brücke et al., Eur. J. Pharmacol. 148, 445 (1988). Radioreceptor assay in biological fluids: R. Lapka et al., J. Pharmacol. Methods 11, 263 (1984). Pharmacokinetics in humans: W. Krause et al., Eur. J. Clin. Pharmacol. 27, 335 (1984). Clinical evaluation in Huntington's disease: S. Bassi et al., Neurology 36, 984 (1986); in Parkinson's disease: T. Brücke et al., Adv. Neurol. 45, 573 (1986); I. Suchy et al., ibid. 577; in hyperprolactinemia and acromegaly: D. Dallabonzana et al., J. Clin. Endocrinol. Metab. 63, 1002 (1986).
Antiparkinsonian; antihyperprolactinemic.
Antiparkinsonian; Prolactin Inhibitor